comprehensive -WSS

comprehensive

author：explore 2025-09-03 09:35:04 - browse：4

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

focus

WSS

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

AI gets buy

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Plastic surgeons increase patient psychiatric screenings

Gene editing the human germline: What are the risks?

Problems with a popular proposal to regulate AI in health care

leisure time

comprehensive

entertainment

Peter Hotez and the public health issue of online harassment

Positive childhood experiences can help future health

Medical leaders decry Supreme Court decision on affirmative action

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Novavax promises a turnaround & Lilly roils the obesity market

Health AI adoption puts security, privacy startups on investors' radar

Wildfire smoke exposes gaps in outdoor worker protections

5 to watch: Tech startups trying to solve health care's staffing crisis

Hollywood unions extend contract negotiations for actors

Padmanee Sharma of MD Anderson at center of lawsuit over credit

focus

AstraZeneca to buy developer of next

Cano Health’s bankruptcy is a warning for Medicare Advantage

Neuroscience’s long legacy of racism

Orchard's therapy for neuron disease in children wins FDA approval

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Intermittent fasting comes with a heart risk? Not so fast

focus

focus

knowledge

focus